This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Ibrance

Pfizer Inc.

Drug Names(s): palbociclib, PD-991, PD-0332991, PD-332,991, PD 0332991, PF-0332991, PF-332991

Description: Palbociclib (PD-332991) is an oral, small molecule cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor.

Deal Structure: Onyx and Warner-Lambert
In May 1995, Onyx entered into a research and development collaboration agreement with Warner-Lambert Company, now a subsidiary of Pfizer, to discover and commercialize small molecule drugs that restore control of, or otherwise intervene in, the misregulated cell cycle in tumor cells. Under this agreement, Onyx developed screening tests, or assays, for jointly selected targets, and transferred these assays to Pfizer for screening of their compound library. The discovery research term ended in August 2001. Pfizer is responsible for subsequent medicinal chemistry, preclinical and clinical development, regulatory filings, manufacture and sale of any approved collaboration compounds. Onyx is entitled to receive payments upon achievement of certain clinical development milestones and registration of any resulting products and is entitled to receive an 8% royalty on worldwide sales.

Onyx and Amgen
In August 2013, Amgen and Onyx announced...See full deal structure in Biomedtracker

Partners: Amgen, Inc.


Ibrance News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug